Riskpilot← Back to searchSign inGet full accessHLA mottagning 2 AB
ABActiveOrg 5591944862StockholmMedical specialists activities · NACE 8622Est. 20190 employees
Revenue 2024
SEK 2M
+6% vs 2023
EBITDA margin
1.3%
+1638% vs 2023
Equity ratio
33.7%
Financial strength
Net profit 2024
SEK 24K
+2171% vs 2023
| Revenue | SEK 2M | +6% |
| EBITDA | SEK 27K | +1638% |
| Net profit | SEK 24K | +2171% |
| Total assets | SEK 353K | -11% |
| Equity | SEK 119K | +25% |
| Employees | 0 | — |
Legal name
HLA mottagning 2 AB
Org number
5591944862
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
11 februari 2019
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna
Company purpose
Föremålet för bolagets verksamhet är att tillhandahålla lokaler och service åt läkarpraktik samt därmed förenlig verksamhet.
Address
Stockholm
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 436 | 1 832 | 1 548 | 1 911 | 2 019 |
| Staff expenses | — | — | −11 | −41 | −12 |
| EBITDA | 283 | 51 | −132 | −2 | 27 |
| Depreciation & amort. | −0 | −10 | −14 | −14 | −3 |
| EBIT | 283 | 41 | −146 | −15 | 24 |
| Net financials | — | — | −0 | −0 | −0 |
| Profit before tax | 212 | 30 | −146 | 0 | 24 |
| Tax | −45 | −6 | 2 | −2 | — |
| Net profit | 167 | 24 | −145 | −1 | 24 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 514 | 514 | 354 | 396 | 353 |
| Equity | 217 | 241 | 96 | 95 | 119 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 226 | 191 | 176 | 235 | 169 |
| Total debt | 226 | 191 | 176 | 235 | 169 |
EBITDA margin
1.3%
This company
15.8%
Market median
-92% vs market
20202024
Equity ratio
33.7%
This company
38.2%
Market median
+12% vs market
20202024
Return on equity
19.9%
This company
18.4%
Market median
+8% vs market
20202024
Net profit margin
1.2%
This company
8.1%
Market median
-85% vs market
20202024
Asset turnover
5.72×
This company
1.12×
Market median
+411% vs market
20202024
Debt / equity
1.97×
This company
0.62×
Market median
-218% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Chairman | 2022 | |
| Board of Directors | 2021 | |
| Former (1) | ||
| Chairman | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of HLA mottagning 2 AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Faris A Hamid Al Khalili | Board of Directors | 0 companies |
| Mohanna Mahmoud Alavi | Board of Directors | 0 companies |
| Farah Aghaie | Board of Directors | 0 companies |
| Eva Therése Lindgren | Chairman | 0 companies |
| Per Kasten Olof Bror Rönnow | Chairman | 0 companies |
| Eva Maria Christina Jarnert | Board of Directors | 0 companies |